BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu C, Schönke M, Zhou E, Li Z, Kooijman S, Boon MR, Larsson M, Wallenius K, Dekker N, Barlind L, Peng XR, Wang Y, Rensen PCN. Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis. Cardiovasc Res 2021:cvab076. [PMID: 33693480 DOI: 10.1093/cvr/cvab076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu X, Zhang H, Zhang S, Mao W, Liu L, Deng C, Hu CH. Olanzapine-induced decreases of FGF21 in brown adipose tissue via histone modulations drive UCP1-dependent thermogenetic impairment. Prog Neuropsychopharmacol Biol Psychiatry 2023;122:110692. [PMID: 36509252 DOI: 10.1016/j.pnpbp.2022.110692] [Reference Citation Analysis]
2 Liu C, Song Z, Li Z, Boon MR, Schönke M, Rensen PCN, Wang Y. Dietary choline increases brown adipose tissue activation markers and improves cholesterol metabolism in female APOE*3-Leiden.CETP mice. Int J Obes (Lond) 2023. [PMID: 36732416 DOI: 10.1038/s41366-023-01269-6] [Reference Citation Analysis]
3 Griffett K, Burris TP. Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases. Front Med 2023;10. [DOI: 10.3389/fmed.2023.1102469] [Reference Citation Analysis]
4 Blackwell JA, Stanford KI. Exercise-induced intertissue communication: adipose tissue and the heart. Curr Opin Physiol 2023;31:100626. [PMID: 36588657 DOI: 10.1016/j.cophys.2022.100626] [Reference Citation Analysis]
5 Ziqubu K, Mazibuko-mbeje SE, Mthembu SXH, Mabhida SE, Jack BU, Nyambuya TM, Nkambule BB, Basson AK, Tiano L, Dludla PV. Anti-Obesity Effects of Metformin: A Scoping Review Evaluating the Feasibility of Brown Adipose Tissue as a Therapeutic Target. IJMS 2023;24:2227. [DOI: 10.3390/ijms24032227] [Reference Citation Analysis]
6 Liu Y, Chen M. Neuregulin 4 as a novel adipokine in energy metabolism. Front Physiol 2022;13:1106380. [PMID: 36703934 DOI: 10.3389/fphys.2022.1106380] [Reference Citation Analysis]
7 Tan H, Yue T, Chen Z, Wu W, Xu S, Weng J. Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine. Int J Biol Sci 2023;19:66-88. [PMID: 36594101 DOI: 10.7150/ijbs.73936] [Reference Citation Analysis]
8 Chen Z, Yang L, Liu Y, Huang P, Song H, Zheng P. The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol 2022;13:1089214. [PMID: 36618930 DOI: 10.3389/fphar.2022.1089214] [Reference Citation Analysis]
9 Liu C, Li Z, Song Z, Fan X, Shao H, Schönke M, Boon MR, Rensen PCN, Wang Y. Choline and butyrate beneficially modulate the gut microbiome without affecting atherosclerosis in APOE*3-Leiden.CETP mice. Atherosclerosis 2022;362:47-55. [PMID: 36347649 DOI: 10.1016/j.atherosclerosis.2022.10.009] [Reference Citation Analysis]
10 Li F, Liu X, Wang W, Xu H, Song W, Sun Z. High Throughput Fabrication of Flexible Top-Driven Sensing Probe. Polymers (Basel) 2022;14. [PMID: 36501518 DOI: 10.3390/polym14235124] [Reference Citation Analysis]
11 Liu C, Schönke M, Spoorenberg B, Lambooij JM, van der Zande HJ, Zhou E, Tushuizen ME, Andréasson A, Park A, Oldham S, Uhrbom M, Ahlstedt I, Ikeda Y, Wallenius K, Peng X, Guigas B, Boon MR, Wang Y, Rensen PC. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.. [DOI: 10.1101/2022.09.20.508654] [Reference Citation Analysis]
12 Liu C, Song Z, Li Z, Boon M, Schönke M, Rensen P, Wang Y. Dietary choline activates brown fat to reduce adiposity and cholesterol in APOE*3-Leiden.CETP mice.. [DOI: 10.21203/rs.3.rs-2049041/v1] [Reference Citation Analysis]
13 Alieva AM, Baikova IE, Reznik EV, Valiev RK, Akhmatov IZ, Arakelyan RA, Saryev MN, Nikitin IG. Fibroblast growth factor 21 as a new tool in the multicomponent assessment of cardiovascular diseases. Medical Journal of the Russian Federation 2022;28:75-88. [DOI: 10.17816/medjrf108900] [Reference Citation Analysis]
14 Li X, Zhang Y, Su L, Cai L, Zhang C, Zhang J, Sun J, Chai M, Cai M, Wu Q, Zhang C, Yan X, Wang L, Huang X. FGF21 alleviates pulmonary hypertension by inhibiting mTORC1/EIF4EBP1 pathway via H19. J Cell Mol Med 2022;26:3005-21. [PMID: 35437883 DOI: 10.1111/jcmm.17318] [Reference Citation Analysis]
15 Wu G, Wu S, Yan J, Gao S, Zhu J, Yue M, Li Z, Tan X. Fibroblast Growth Factor 21 Predicts Short-Term Prognosis in Patients With Acute Heart Failure: A Prospective Cohort Study. Front Cardiovasc Med 2022;9:834967. [PMID: 35369322 DOI: 10.3389/fcvm.2022.834967] [Reference Citation Analysis]
16 Zhang Y, Liu D, Long XX, Fang QC, Jia WP, Li HT. The role of FGF21 in the pathogenesis of cardiovascular disease. Chin Med J (Engl) 2021;134:2931-43. [PMID: 34939977 DOI: 10.1097/CM9.0000000000001890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]